Everything below concerns thymalfasin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-17. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
protein-coding gene A gene containing a coding sequence which can be transcribed and translated to produce a protein, as opposed to an RNA gene, which produces non-coding RNA transcripts that are not translated into proteins but instead have functions in and of themselves.
== Toxicity == The toxicity of organomercury compounds presents both dangers and benefits. Dimethylmercury in particular is notoriously toxic, but found use as an antifungal agent and insecticide. Merbromin and phenylmercuric borate are used as topical antiseptics, while thimerosal is safely used as a preservative for vaccines and antitoxins.
== History == The discovery and characterization of aminopeptidases date back to the early 20th century. The term "aminopeptidase" was first introduced in 1929 by Linderstrøm-Lang and Sato in order to describe enzymes that cleave amino acids from the N-terminus of peptides. In the 1950s and 1960s, the discovery of leucine aminopeptidase (LAP) and aminopeptidase N (APN) marked important milestones in the field. LAP was found to be crucial for protein digestion, while APN was recognized for its role in the regulation of peptide-mediated effects. These discoveries were pivotal in understanding the physiological functions of aminopeptidases and their involvement in health and disease. The subsequent decades saw extensive research into the structure, function, and mechanisms of action of various aminopeptidases. For example, the M1 family of aminopeptidases, which includes puromycin-sensitive aminopeptidase (PSA), was characterized by conserved zinc-dependent sites and exopeptidase motifs. The study of PSA in different model organisms revealed its essential roles in growth and behavior. Mutations in orthologs of PSA in different species were linked to errors in meiosis and reduced viability of embryos. Aminopeptidase N, also known as AP-N or CD13, was extensively characterized for its broad substrate specificity (ability to bind to its targets) and its presence in various tissues such as the brush border membranes of the kidney, small intestine, and placenta.
Ligamentous laxity or ligament laxity can appear in a variety of ways and levels of severity. In most people, ligaments (which are the tissues that connect bones to each other) are naturally tight in such a way that the joints are restricted to 'normal' ranges of motion. This creates normal joint stability. If muscular control does not compensate for ligamentous laxity, joint instability may result. The trait is almost certainly hereditary, and is usually something the affected person would just be aware of, rather than a serious medical condition. However, if there is widespread laxity of other connective tissue, then this may be a sign of Ehlers–Danlos syndrome, Down syndrome, Klippel–Feil syndrome, juvenile idiopathic arthritis, Larsen syndrome, Marfan syndrome, osteogenesis imperfecta, and other medical conditions. Ligamentous laxity may also result from injury, such as from a vehicle accident. It can result from whiplash and be overlooked for years by doctors who are not looking for it, despite the chronic pain that accompanies the resultant spinal instability. Ligamentous laxity will show up on an upright magnetic resonance imaging (MRI), the only kind of MRI that will show soft tissue damage. It can only be inferred from a digital motion x-ray.
Sources: en.wikipedia.org
==== Food industry ==== The PEG–NaCl system has been shown to be effective at partitioning small molecules, such as peptides and nucleic acids. These compounds are often flavorants or odorants. The system could then be used by the food industry to isolate or eliminate particular flavors. Caffeine extraction used to be done using liquid–liquid extraction, specifically direct and indirect liquid–liquid extraction (Swiss Water Method), but has since moved towards super-critical CO2 as it is cheaper and can be done on a commercial scale.
Rumors also surfaced in February 2022 that El Mencho died in a private hospital in Guadalajara. This would later be backed by narcomantas (banners displaying warnings to police and other cartels) which appeared around the city of Colima, and which were written by Mezcales, which up until this report of El Mencho's death, acted as the CJNG's local enforcers.
Detrital zircon geochronology is a scientific technique for understanding the age and provenance of sedimentary deposits. To determine the age of zircons deposited within a specific sedimentary unit, mass spectrometry is used to measure the abundance of radioisotopes in the grains, most commonly the uranium–lead ratio. Zircon is a common accessory or trace mineral constituent of most granite and felsic igneous rocks. Due to its hardness, durability and chemical inertness, zircon persists in sedimentary deposits and is a common constituent of most sands. Zircons contain trace amounts of uranium and thorium and can be dated using several modern analytical techniques. Detrital zircon geochronology has become increasingly popular in geological studies from the 2000s mainly due to the advancement in radiometric dating techniques. Detrital zircon age data can be used to constrain the maximum depositional age, determine provenance, and reconstruct the tectonic setting on a regional scale.
But when he finally presented his results he reported an excess heat of only one degree Celsius, a result that could be explained by chemical differences between heavy and light water in the presence of lithium. He had not tried to measure any radiation and his research was derided by scientists who saw it later. For the next six weeks, competing claims, counterclaims, and suggested explanations kept what was referred to as "cold fusion" or "fusion confusion" in the news. In April 1989, Fleischmann and Pons published a "preliminary note" in the Journal of Electroanalytical Chemistry. This paper notably showed a gamma peak without its corresponding Compton edge, which indicated they had made a mistake in claiming evidence of fusion byproducts. Fleischmann and Pons replied to this critique, but the only thing left clear was that no gamma ray had been registered and that Fleischmann refused to recognize any mistakes in the data. A much longer paper published a year later went into details of calorimetry but did not include any nuclear measurements. Nevertheless, Fleischmann and Pons and a number of other researchers who found positive results remained convinced of their findings. The University of Utah asked Congress to provide $25 million to pursue the research, and Pons was scheduled to meet with representatives of President Bush in early May. On 30 April 1989, cold fusion was declared dead by The New York Times. The Times called it a circus the same day, and the Boston Herald attacked cold fusion the following day.
Exhibitors from outside Tamil Nadu also echoed similar views. Arora Talkies (Mumbai) described Darbar as the most profitable Tamil film screened at their theatre, while exhibitors in Karnataka reported a favourable audience response. Several theatre owners dismissed circulating reports of losses as “rumours” and emphasised that the film delivered satisfactory returns at the exhibition level.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.